c‐Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme
Open Access
- 8 April 2009
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 218 (3), 292-300
- https://doi.org/10.1002/path.2564
Abstract
Genomic amplification of c-Jun and its upstream kinases have been implicated as a mechanism of progression from well-differentiated to dedifferentiated liposarcoma. To further define the role of c-Jun in liposarcoma progression, we performed immunohistochemistry for c-Jun and its activating kinase ASK1 on a series of liposarcomas (n = 81). We correlated the results with fluorescence in situ hybridization to detect c-Jun amplification. We also derived new cell lines from dedifferentiated liposarcomas with c-Jun amplification. c-Jun protein is expressed in the majority of dedifferentiated liposarcomas (91%) and their well-differentiated components (59%), but only in the minority of pure well-differentiated liposarcomas (27%). When c-Jun is amplified in dedifferentiated liposarcoma, it is interspersed with amplified MDM2 on ring and giant marker chromosomes. MDM2 amplification is one of the earliest events in liposarcoma development, and these results suggest that c-Jun was amplified at a similar time in the evolution of the tumour. In addition, shRNA to c-Jun in c-Jun-amplified liposarcoma cells reduces cell number in vitro and inhibits tumour formation in vivo without an observable effect on the differentiation state of the liposarcoma cells. Thus, c-Jun amplification is oncogenic in liposarcomas but not always sufficient for inhibition of adipocytic differentiation. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- Molecular Oncologic Pathology of the Dana Farber Cancer Institute and Brigham and Women's Hospital
This publication has 18 references indexed in Scilit:
- Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacyCancer Biology & Therapy, 2008
- HMGA2 is the partner of MDM2 in well‐differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent ampliconInternational Journal of Cancer, 2008
- Pairwise comparison of genomic imbalances between primary and recurrent well differentiated liposarcomasCancer Genetics and Cytogenetics, 2007
- JUN Oncogene Amplification and Overexpression Block Adipocytic Differentiation in Highly Aggressive SarcomasCancer Cell, 2007
- ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14–q15 and 6q23 amplificationsGenes, Chromosomes and Cancer, 2004
- A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomasCancer Genetics and Cytogenetics, 2002
- Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma:Cancer Genetics and Cytogenetics, 2001
- Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumorsGenes, Chromosomes and Cancer, 1999
- Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs.Journal of Bone and Joint Surgery, 1996
- Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21–q22 in soft tissue sarcomasGenes, Chromosomes and Cancer, 1995